Eli Lilly (LLY) Share-based Compensation (2009 - 2026)

Eli Lilly has reported Share-based Compensation for 18 years, with the latest figure at $161.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 4.55% year-over-year to $161.0 million; the trailing twelve-month figure through Mar 2026 stood at $633.0 million (down 1.19% YoY), and the FY2025 full-year result was $626.0 million, down 3.1% from the prior year.
• Share-based Compensation for Q1 2026 stood at $161.0 million, up from $136.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $215.6 million in Q3 2023, with the low at $85.1 million in Q3 2022.
• Historically, Share-based Compensation has averaged $143.1 million across 5 years, with a median of $142.3 million in 2024.
• Annual changes were most pronounced in 2023 — Share-based Compensation soared 153.35% — and 2024, when it plunged 38.22%.
• Eli Lilly's Share-based Compensation stood at $92.9 million in 2022, then climbed by 29.92% to $120.7 million in 2023, then advanced by 17.9% to $142.3 million in 2024, then slipped by 4.36% to $136.1 million in 2025, then climbed by 18.3% to $161.0 million in 2026.
• The last three Share-based Compensation figures came in at $161.0 million (Q1 2026), $136.1 million (Q4 2025), and $151.1 million (Q3 2025), per Business Quant data.